Capstone Investment Advisors LLC Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)

Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics plc (NASDAQ:AUTL) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,951 shares of the company’s stock, valued at approximately $51,000.

Several other hedge funds also recently made changes to their positions in AUTL. FMR LLC lifted its position in Autolus Therapeutics by 44.6% during the third quarter. FMR LLC now owns 17,773,873 shares of the company’s stock valued at $64,519,000 after buying an additional 5,478,706 shares during the period. Great Point Partners LLC lifted its position in Autolus Therapeutics by 195.0% during the 2nd quarter. Great Point Partners LLC now owns 3,441,667 shares of the company’s stock valued at $11,977,000 after acquiring an additional 2,275,000 shares during the period. Armistice Capital LLC boosted its stake in Autolus Therapeutics by 33.8% during the second quarter. Armistice Capital LLC now owns 6,250,000 shares of the company’s stock worth $21,750,000 after acquiring an additional 1,578,000 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Autolus Therapeutics by 74.5% in the second quarter. Bank of New York Mellon Corp now owns 2,531,688 shares of the company’s stock worth $8,810,000 after purchasing an additional 1,080,897 shares during the period. Finally, Affinity Asset Advisors LLC increased its stake in shares of Autolus Therapeutics by 27.4% during the second quarter. Affinity Asset Advisors LLC now owns 4,300,000 shares of the company’s stock valued at $14,964,000 after purchasing an additional 925,000 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Up 1.5 %

Shares of AUTL opened at $3.32 on Monday. Autolus Therapeutics plc has a twelve month low of $2.69 and a twelve month high of $7.45. The company has a market capitalization of $883.42 million, a P/E ratio of -2.74 and a beta of 2.04. The firm has a 50 day moving average of $3.72 and a 200 day moving average of $3.91.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period last year, the company earned ($0.26) earnings per share. On average, sell-side analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on AUTL. Redburn Atlantic raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Friday, November 15th. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $9.00 target price on shares of Autolus Therapeutics in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $10.15.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.